Abstract:Parkinson's disease (PD) is among the most prevalent neurodegenerative disorders, affecting over 10 million people worldwide. The protein encoded by the SNCA gene, alpha‐synuclein (ASYN), is the major component of Lewy body (LB) aggregates, a histopathological hallmark of PD. Mutations and posttranslational modifications (PTMs) in ASYN are known to influence protein aggregation and LB formation, possibly playing a crucial role in PD pathogenesis. In this work, we applied computational methods to characterize the effects of missense mutations and PTMs on the structure and function of ASYN. Missense mutations in ASYN were compiled from the literature/databases and underwent a comprehensive predictive analysis. Phosphorylation and SUMOylation sites of ASYN were retrieved from databases and predicted by algorithms. ConSurf was used to estimate the evolutionary conservation of ASYN amino acids. Molecular dynamics (MD) simulations of ASYN wild‐type and variants A30G, A30P, A53T, and G51D were performed using the GROMACS package. Seventy‐seven missense mutations in ASYN were compiled. Although most mutations were not predicted to affect ASYN stability, aggregation propensity, amyloid formation, and chaperone binding, the analyzed mutations received relatively high rates of deleterious predictions and predominantly occurred at evolutionarily conserved sites within the protein. Moreover, our predictive analyses suggested that the following mutations may be possibly harmful to ASYN and, consequently, potential targets for future investigation: K6N, T22I, K34E, G36R, G36S, V37F, L38P, G41D, and K102E. The MD analyses pointed to remarkable flexibility and essential dynamics alterations at nearly all domains of the studied variants, which could lead to impaired contact between NAC and the C‐terminal domain triggering protein aggregation. These alterations may have functional implications for ASYN and provide important insight into the molecular mechanism of PD, supporting the design of future biomedical research and improvements in existing therapies for the disease.

Amyloid Fibers of α-Synuclein Catalyze Chemical Reactions

The Bacterial Amyloids Phenol Soluble Modulins from Staphylococcus aureus Catalyze Alpha-Synuclein Aggregation

Phosphorylation and O-GlcNAcylation at the Same Α-Synuclein Site Generate Distinct Fibril Structures

Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy

Alpha-synuclein phosphorylation induces amyloid conversion via enhanced electrostatic bridging: Insights from molecular modeling of the full-length protein

Parkinson’s disease associated mutation E46K of α-synuclein triggers the formation of a novel fibril structure

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

α-Synuclein Oligomers Displace Monomeric α-Synuclein from Lipid Membranes

3,4‐Dihydroxyphenylethanol and 3,4‐dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α‐synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect

Post-translational Modification of α-Synuclein Modifies Monomer Dynamics and Aggregation Kinetics

Parkinson's disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM.

Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases

Catechol‐induced covalent modifications modulate the aggregation tendency of α‐synuclein: An in‐solution and in‐silico study

O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease

Amyloid accelerator polyphosphate fits as the mystery density in α-synuclein fibrils

Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease

α-Synuclein acts as a cholesteryl-ester sensor on lipid droplets regulating organelle size and abundance.

α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease

Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease